Derivatives of mithramycin and methods of making and uses...

Details Derivatives of mithramycin and methods of making and uses... Derivatives of mithramycin and methods of making and uses...

2008-09-09

2008-09-09

Swartz, Rodney P. (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C435S041000, C424S093430, C424S278100, C424S282100

Reexamination Certificate

active

10796304

ABSTRACT:
The invention, in one aspect, generally relates to mithramycin derivatives from mutatedStreptomyces argillaceusand their production. The invention also relates using the derivatives for the treatment of various diseases. Finally, the invention relates to a mutatedStreptomyces argillaceususeful in the production of the mithramycin derivatives.

REFERENCES:
patent: 3592925 (1971-07-01), Evans, Jr. et al.
patent: 3646194 (1972-02-01), Sobin et al.
patent: 3821085 (1974-06-01), Zhdanovich et al.
patent: 3906093 (1975-09-01), Sobin et al.
patent: 4141974 (1979-02-01), Davies et al.
patent: 4452786 (1984-06-01), Mitsuhashi et al.
patent: 4511560 (1985-04-01), Tomita et al.
patent: 4935445 (1990-06-01), Merry
patent: 5057304 (1991-10-01), Kretzschmar et al.
patent: 5656736 (1997-08-01), Nakano et al.
patent: 5723448 (1998-03-01), Gross et al.
Lily L. Remsing, et al. “Mithramycin SK, A Novel Antitumor Drug with Improved Therapeutic Index, Mithramycin SA, and Demycarosyl-mithramycin SK: Three New Products Generated in the Mithramycin ProducerStreptomyces argillaceusthrough Combinatorial Biosynthesis” J. Am. Chem. Soc. 2003, 125, pp. 5745-5753.
Robert J. Ferrante, et al. “Chemotherapy for the Brain: Mithramycin Prolongs Survival in a Model of Huntington's Disease”.
L. Prado, et al. “Analysis of two chromosomal regions adjacent to genes for a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin inStreptomyces argillaceus.” 1: Mol Gen Genet. Mar. 1999;261(2):216-25.
G. Blanco, et al. “Characterization of two glycosyltransferases involved in early glycosylation steps during biosynthesis of the antitumor polyketide mithramycin byStreptomyces argillaceus.” 1: Mol Gen Genet. Jan. 2000;262(6):991-1000.
MJ Lozano, et al. “Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin byStreptomyces argillaceus.” 1: J Biol Chem. Feb. 4, 2000;275(5):3065-74.
J. Kantola, et al. “Folding of the polyketide chain is not dictated by minimal polyketide synthase in the biosynthesis of mithramycin and anthracycline.” 1: Chem Biol. Oct. 1997;4(10):751-5.
L. Prado, et al. “Oxidative cleavage of premithramycin B is one of the last steps in the biosynthesis of the antitumor drug mithramycin.” 1: Chem Biol. Jan. 1999;6(1):19-30.
E. Fernandez, et al. “Identification of two genes fromStreptomyces argillaceusencoding glycosyltransferases involved in transfer of a disaccharide during biosynthesis of the antitumor drug mithramycin.” 1: J Bacteriol. Sep. 1998;180(18):4929-37.
D Rodriguez, et al. “Purification and characterization of a monooxygenase involved in the biosynthetic pathway of the antitumor drug mithramycin.” 1: J Bacteriol. Jul. 2003;185(13):3962-5.
D Rodriguez, et al. “MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction.” 1: J Biol Chem. Dec. 5, 2003 [Epub ahead of print].
A. Gonzalez, et al. “The mtmVUC genes of the mithramycin gene cluster inStreptomyces argillaceusare involved in the biosynthesis of the sugar moleties.” Molecular and General Genetics, (Feb. 2001) vol. 264, No. 6, pp. 827-835. Springer-Verlag, New York.
Lily L. Remsing, et al. “Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosysnthesis of the deoxysugar moieties of the antitumor drug mithramycin byStreptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway.” Journal of the American Chemical Society, (Feb. 27, 2002) 124 (8) 1606-14.
Axel Trefzer, et al. “Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways.” Journal of the American Chemical Society, (May 29, 2002) 124 (21) 6056-62.
J. Plowman, et al. “Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice.” Cancer Research, (Feb. 15, 1995) 55 (4) 862-7.
P. H. Viollier, et al. “Role of acid metabolism inStreptomyces coelicolormorphological differentiation and antibiotic biosynthesis.” Journal of Bacteriology, (May 2001) 183 (10) 3184-92.
Lily L Remsing, et al. “Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.” Biochemistry, (Jul. 15, 2003) 42 (27) 8313-24.
K. Stajner, et al. “Variability and strain selection inStreptomyces atroollvaceus. II. Chromatographic analysis of mithramycin-producing and nonproducing strains.” Folla Microbiologica (Prague, Czech Republic) (1974), 19(6), 498-506.
G. Blanco, et al. “Identification of a sugar flexible glycosyltransferase fromStreptomyces olivaceus, the producer of the antitumor polyketide elloramycin.” Chemistry and Biology, (Mar. 2001) 8 (3) 253-63.
M J F Lozano, et al. “Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin byStreptomyces argillaceus.” Journal of Biological Chemistry, (Feb. 4, 2000) vol. 275, No. 5, pp. 3065-3074. Publisher: Amer Soc Biochemistry Molecular Biology Inc, Bethesda, MD.
Lily L. Remsing, et al. “Mithramycin SK, a novel aureolic acid-type antitumor compound generated by combinatorial biosynthesis, shows an improved therapeutic index compared to mithramycin in in vitro antitumor and toxicity assays.” 2003, American Association for Cancer Research. 2003 Proceedings of the AACR <http://aacr03.agora.com/planner/displayabstract.asp?presentationId=9968>.
Sukalyan Chatterjee, PhD, et al. “Sequence-Selective DNA Binding Drugs Mithramycin A and Chromomycin A3Are Potent Inhibitors of Neuronal Apoptosis Induced by Oxidative Stress and DNA Damage in Cortical Neurons.” Annals of Neurology, vol. 49, No. 3, Mar. 2001, Wiley-Liss, Inc., pp. 345-354.
Lily L. Remsing, et al. “Ketopremithramycins and Ketomithramycins, Four New Aureolic Acid-Type Compounds Obtained upon inactivation of Two Genes Involved in the Biosynthesis of the Deoxysugar Moieties of the Antitumor Drug Mithramycin byStreptomyces argillaceus, Reveal Novel Insights into Post-PKS Tailoring Steps of the Mithramycin Biosynthetic Pathway.” J. Am. Chem. Soc., vol. 124, No. 8, 2002, pp. 1606-1614.

Affiliated with

Also associated with

Rating

Derivatives of mithramycin and methods of making and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of mithramycin and methods of making and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of mithramycin and methods of making and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3904044